Tirzepatide Lyophilized Hmoovyog ib hom tshuaj uas npaj siv khov- tshuab ziab khaub ncaws, nrog rau cov khoom xyaw nquag yog Tirzepatide. Lyophilization thev naus laus zis tshem tawm cov dej noo los ntawm qis- kub sublimation, hloov cov tshuaj mus rau hauv xoob thiab porous khoom hmoov.Cov txheej txheem no tuaj yeem txhim kho kev ruaj ntseg ntawm cov tshuaj, txuas lub txee lub neej, thiab txo qis kev pheej hmoo ntawm kev thauj mus los thiab khaws cia.Raws li cov tshuaj tshiab, Tirzepatide cov yam ntxwv tseem ceeb nyob hauv nws cov kev ua haujlwm dual agonist. Nws tsom rau ob qho tib si qabzib nyob ntawm insulinotropic polypeptide (GIP) receptors thiab glucagon zoo li peptide-1 (GLP-1) receptors, ua tiav ob lub hom phiaj ntawm kev tswj ntshav qabzib thiab tswj qhov hnyav los ntawm simulating lub cev muaj zog ntawm ob lub plab cov tshuaj hormones. GIP thiab GLP-1 yog ob qho tib si zais los ntawm txoj hnyuv. Cov qub feem ntau txhawb nqa insulin secretion thiab inhibits gastric acid secretion, thaum lub tom kawg tswj cov ntshav qab zib los ntawm kev ncua lub plab zom mov, txo qis qab los noj mov, thiab txhawb nqa cov tshuaj insulin secretion.Tirzepatide integrates ob insulin txhawb kev cuam tshuam rau hauv ib qho molecule, tsim cov tshuaj tshiab rau kev kho mob ntshav qab zib hom 2.
Peb tsis tsuas yog muab cov hmoov ntshiab thiab cov tshuaj ntsiav, tab sis kuj muaj lwm cov ntaub ntawv noj. Yog tias tsim nyog, thov hu rau peb pab neeg muag khoom.
Peb cov khoom
Tirzepatide COA
Tirzepatide Lyophilized Hmoovyog cov ntaub ntawv tseem ceeb ntawm GIP/GLP -1 receptor dual agonist. Cov txheej txheem khov-drying ua kom nws ruaj khov hauv kev khaws cia thiab kev thauj mus los. Nws cov ntsiab lus siv tsom rau kev kho mob ntshav qab zib hom 2, rog rog thiab cuam tshuam txog kev tswj hwm kab mob metabolic, kev tshawb fawb soj ntsuam thiab kev kho mob yooj yim, nrog rau kev npaj tshuaj thiab kev tsim khoom. Nws kuj qhia tau hais tias muaj peev xwm siv tus nqi hauv plawv plawv, neurometabolic thiab lwm yam.
Cov yam ntxwv tseem ceeb hauv paus thiab tus nqi ntawm khov - cov ntaub ntawv siv tshuaj qhuav qhuav
Qhov tseem ceeb ntawm Matter thiab Mechanism of Action
Tirzepatide yog ib qho kev sib xyaw ua ke peptide uas ua raws li ob lub agonist ntawm GIP (glucose dependent insulinotropic polypeptide) thiab GLP-1 (glucagon zoo li peptide-1) receptors, nrog rau kev sib koom ua ke ntawm kev ua haujlwm.
GLP-1 receptor activation: txhawb nqa cov piam thaj hauv cov tshuaj insulin secretion, inhibits glucagon tso tawm, ncua lub plab zom mov kom txo qis cov ntshav qabzib tom qab hloov pauv, thiab ua rau lub hauv paus paj hlwb kom txo qis qab los noj mov thiab txo calorie kom tsawg.
GIP receptor activation: txhim kho insulin rhiab heev, txhim kho beta cell muaj nuj nqi, thiab koom nrog GLP-1 receptors txhawm rau txhim kho cov ntshav qabzib ntxiv. Nws tseem ua lub luag haujlwm pabcuam hauv kev tswj hwm qhov hnyav, txhawb kev hloov pauv ntawm cov rog dawb rau cov rog xim av thiab ua kom lub zog siv nyiaj ntau dua.
Qhov tshwj xeeb zoo ntawm khov- cov hmoov qhuav
Kev ziab kom qhuav yog txheej txheem ntawm kev tshem dej los ntawm cov kua Tirzepatide los ntawm sublimation nyob rau hauv lub tshuab nqus tsev ib puag ncig tom qab khov. Tus nqi tseem ceeb ntawm cov qauv no yog xav txog hauv cov hauv qab no:
| Feature | Tshwj xeeb zoo | Daim ntawv thov scenario tus nqi |
| Kev txhim kho kev ruaj ntseg | Nws tuaj yeem khaws cia rau lub sijhawm ntev (feem ntau 2-3 xyoos) ntawm 2-8℃kom tsis txhob muaj qhov txo qis ntawm peptides los ntawm hydrolysis thiab oxidation. | Ua kom yooj yim - teev ntau lawm, kev thauj mus los, thiab chaw kho mob khaws cov khoom siv tshuaj |
| Purity tu | Lub khov- txheej txheem ziab kom qhuav tshem tawm cov dej noo thiab qee qhov impurities, thiab purity ntawm cov khoom tiav tuaj yeem ncav cuag ntau dua 99% | Xyuas kom meej qhov sib xws ntawm cov tshuaj ua tau zoo ntawm cov qauv thiab txo qhov kev pheej hmoo ntawm kev phiv tshuaj |
| Kev yooj yim ntawm kev kho dua tshiab | Nws tuaj yeem yaj sai sai nrog dej txhaj tshuaj lossis dej tshuaj tua kab mob los tsim cov tshuaj ntshiab rau kev txhaj tshuaj subcutaneous | Kho kom haum rau cov kev xav tau ntawm kev kho tshuaj sai sai thiab ua kom yooj yim npaum li kev teeb tsa hauv kev tshawb fawb tshawb fawb |
| Muaj tseeb thiab tswj tau ntau npaum li cas | Tau ntim rau hauv cov kev qhia tshwj xeeb (xws li 10mg, 30mg, 50mg / lub raj mis), qhov ntau npaum li cas tuaj yeem raug kho kom raug tom qab rov kho dua. | Ua tau raws li tus kheej xav tau kev kho mob ntawm cov neeg mob sib txawv (xws li ntshav qab zib thiab rog) |
Cov hom phiaj kho mob tseem ceeb
Tirzepatide Lyophilized Hmoovyog cov khoom siv tseem ceeb rau kev npaj cov tshuaj ntshav qab zib xws li Mounjaro, uas muaj txiaj ntsig tsis tuaj yeem hloov pauv hauv kev kho mob ntshav qab zib hom 2. Nws tuaj yeem siv rau kev tswj hwm cov ntshav qabzib thiab tuaj yeem txo glycosylated hemoglobin (HbA1c). Cov ntaub ntawv kho mob qhia tau hais tias thaum ua ke nrog basal insulin lossis metformin, Tirzepatide tuaj yeem txo cov neeg mob 'HbA1c los ntawm 1.5% -2.0%, uas zoo dua rau qee lub hom phiaj GLP-1 receptor agonists. Nws ob txoj kev ua haujlwm ib txhij tuaj yeem tswj hwm cov ntshav qabzib sai thiab cov ntshav qabzib tom qab, txo cov ntshav qabzib hloov pauv, thiab txo qis kev pheej hmoo ntawm cov teeb meem ntshav qab zib. Nws tseem tuaj yeem txo qhov kev pheej hmoo ntawm hypoglycemia. Nws yog nyob ntawm glucose. Nws tsuas tuaj yeem txhawb kev tsim cov tshuaj insulin thaum cov ntshav qab zib nce siab, zam kev tsis pom kev tsis zoo ntawm cov tshuaj insulin hauv cov tshuaj insulin. Nws yog qhov tshwj xeeb tshaj yog rau cov neeg laus lossis cov neeg mob ntshav qab zib hom 2 uas muaj lub siab thiab lub raum tsis ua haujlwm.
Nws kuj yog siv rau kev tiv thaiv thiab kho ntawm beta cell muaj nuj nqi. Kev siv lub sijhawm ntev tuaj yeem txhim kho txoj haujlwm zais cia ntawm pancreatic beta hlwb thiab ncua tus nqi ntawm beta cell poob. Kev tshawb fawb tau pom tias Tirzepatide tuaj yeem qhib GIP receptors, txhawb nqa - cell proliferation, txo apoptosis, muab cov txiaj ntsig kho mob ntxiv rau cov neeg mob uas muaj kab mob ntev dua thiab ua tsis taus - cell function, thiab ncua kev kis kab mob. Ntxiv nrog rau cov ntshav qabzib, nws tseem tuaj yeem txo qis - ntom lipoprotein cholesterol (LDL - C) thiab triglycerides hauv cov neeg mob, txhim kho cov ntshav lipid profile, txo qis insulin tsis kam, thiab muaj kev sib koom ua ke ntawm cov tsos mob ntawm cov kab mob metabolic feem ntau cuam tshuam nrog hom 2 mob ntshav qab zib. Tom qab rov kho dua ntawm khov- cov hmoov qhuav, nws tuaj yeem npaj rau hauv kev txhaj tshuaj subcutaneous ib hlis ib zaug. Piv nrog rau cov tshuaj hypoglycemic niaj hnub, nws txhim kho kev ua raws li cov neeg mob noj tshuaj, tshwj xeeb tshaj yog tsim nyog rau cov neeg ua haujlwm tsis khoom thiab cov neeg laus uas nquag noj tshuaj. Feem ntau siv pib koob tshuaj hauv kev kho mob yog 2.5mg / lub lis piam, maj mam titrated rau 5mg, 10mg, lossis 15mg / lub lis piam raws li kev tswj ntshav qabzib.
Zepbound, uas siv Tirzepatide khov- cov hmoov qhuav ua cov khoom siv raw, yog cov tshuaj pom zoo los ntawm FDA rau kev kho mob rog. Nws yog lub hom phiaj poob phaus rau kev rog rog hnyav, thiab siv tau rau cov neeg laus laus uas muaj BMI Ntau dua lossis sib npaug li 30kg / m ², lossis BMI Ntau dua lossis sib npaug li 27kg / m² thiab cov teeb meem rog rog xws li kub siab, hyperlipidemia, thiab ntshav qab zib hom 2. Cov kev tshawb fawb soj ntsuam tau pom tias qhov siab - koob tshuaj (15mg / lub lis piam) Tirzepatide kev kho mob rau 72 lub lis piam ua rau qhov hnyav poob ntawm 15% -20% hauv cov neeg mob, zoo dua li cov tshuaj poob phaus thiab tib lub hom phiaj GLP-1 receptor agonists. Kev tswj hwm ob txoj kev qab los noj mov thiab cov metabolism txo qis calorie kom tsawg los ntawm kev noj qab haus huv hauv nruab nrab, thaum ncua lub plab zom mov thiab ua kom ntev satiety. Nws tseem tuaj yeem tswj hwm cov metabolism hauv cov rog, txhawb kev rog rog thiab txo cov rog synthesis, ua kom muaj kev noj qab haus huv yuag poob ntawm "txo cov rog tsis tau poob" thiab txhim kho lub cev muaj pes tsawg leeg.
Kev pabcuam kev txhim kho ntawm cov teebmeem kev rog rog yog obstructive pw tsaug zog apnea (OSA) cuam tshuam nrog kev rog, uas tuaj yeem txo qis los ntawm kev poob phaus kom txo tau cov hlab ntsws compression thiab txhim kho qhov zaus ntawm apnea; Rau kev rog rog txog kev sib koom tes, kev poob phaus tuaj yeem txo qis kev sib koom tes thiab txo cov tsos mob ntawm tus mob; Nyob rau tib lub sijhawm, nws tseem tuaj yeem txo qhov kev pheej hmoo ntawm cov kab mob plawv hauv cov neeg mob rog. Nws ntev -lub sij hawm tu lub cev hnyav yog ib qho kev npaj los ntawm khov- cov hmoov qhuav uas tuaj yeem siv los ua cov tshuaj kho kom ntev - tswj qhov hnyav. Tom qab tus neeg mob ncav cuag lub hom phiaj qhov hnyav, qis- kev kho cov tshuaj noj kom tsis txhob hnyav rov qab thiab muab kev daws teeb meem rau kev noj qab haus huv ntawm kev rog.
Cov kev tshawb fawb ua ntej thiab kev sim tshuaj ntsuam xyuas ua ntej tau pom tias Tirzepatide tuaj yeem txo cov kab mob uas tsis yog -Alcoholic fatty siab kab mob (NASH) los ntawm kev txhim kho cov tshuaj insulin, txo cov rog hauv siab, thiab inhibiting daim siab mob. Cov hmoov qhuav qhuav muab cov khoom siv ruaj khov rau kev tshawb fawb soj ntsuam ntawm hom kev nthuav dav no, thiab xav tias yuav dhau los ua kev xaiv tshiab rau kev kho mob NASH. Polycystic zes qe menyuam syndrome feem ntau nrog cov tsos mob xws li insulin tsis kam, rog, thiab hyperandrogenism. Tirzepatide tuaj yeem txhim kho insulin tsis kam, tswj cov qib tshuaj hormones, txo qhov hnyav, pab txhim kho cov neeg mob lub cev ntas thiab kev ua haujlwm ntawm ovulation. Cov khoom ruaj khov ntawm khov- cov hmoov qhuav ua kom yooj yim rau kev sim tshuaj ntsuam xyuas thiab tshawb xyuas cov kev kho tus kheej. Obstructive pw tsaug zog apnea (OSA) yog ib qho teeb meem loj rau kev rog rog, thiab nws cov laj thawj tseem ceeb yog cov rog rog hauv caj dab ua rau cov hlab ntsws stenosis. Tirzepatide txo qis caj dab rog, nthuav dav hauv txoj hlab ntsws, thiab txo qis apnea hypopnea index (AHI) los ntawm kev poob phaus. Cov qauv npaj los ntawm khov- cov hmoov qhuav tuaj yeem siv los ua kev kho mob ntxiv rau OSA, tshwj xeeb tshaj yog rau cov neeg mob uas tsis tuaj yeem zam lub tshuab ua pa.
Clinical and Basic Medical Research Applications
Tirzepatide Lyophilized Hmoovyog ib qho cuab yeej tseem ceeb hauv kev tshawb fawb cov kab mob metabolic vim nws siab purity thiab zoo stability. Nws daim ntawv thov kev tshawb fawb npog ntau qhov ntev:
Kev tshawb fawb txog Metabolic Mechanisms
Kev tshawb nrhiav ntawm receptor signaling pathways
Siv los kawm txog cov kev taw qhia qis qis tom qab kev sib koom ua ke ntawm GIP thiab GLP-1 receptors, xws li kev tswj hwm cov txheej txheem ntawm PI3K / Akt, MAPK thiab lwm txoj hauv kev ntawm cov ntshav qabzib thiab cov roj metabolism, muab lub hauv paus theoretical rau kev txhim kho cov tshuaj ntau lub hom phiaj metabolic.
Kev tshawb fawb txog kev tswj cov roj metabolism
Los ntawm cov qauv tsiaj (xws li cov nas rog rog thiab cov nas ntshav qab zib), saib xyuas cov teebmeem ntawm Tirzepatide ntawm cov rog dawb browning, adipocytes txawv thiab lipolysis, thiab txheeb xyuas nws lub luag haujlwm lub hom phiaj hauv lub zog metabolism.
Kev tshawb fawb txog kev tiv thaiv mechanism ntawm pancreatic islet muaj nuj nqi
Hauv vitro pancreatic islet cell kab lis kev cai lossis hauv vivo kev sim tsiaj, tshawb xyuas qhov cuam tshuam ntawm Tirzepatide ntawm - cell proliferation, apoptosis, thiab insulin secretion function, thiab tshawb nrhiav nws cov txheej txheem molecular ntawm kev ncua kev ua haujlwm ntawm pancreatic islet poob.
Kev sib piv tshuaj thiab kev tshawb fawb optimization
Kawm txog qhov sib txawv ntawm kev kho mob ntawm cov tshuaj zoo sib xws
Siv los sib piv nrog ib leeg lossis triple lub hom phiaj agonists xws li Semaglutide thiab Retatrutide, ntsuas qhov sib txawv ntawm kev tswj cov ntshav qabzib, qhov hnyav poob, kev nyab xeeb, thiab lwm yam, thiab muab cov ntaub ntawv txhawb nqa rau kev xaiv tshuaj kho mob.
Optimization ntawm ntau npaum li cas daim ntawv thiab kev tswj hwm txoj kev
Raws li khov- cov hmoov qhuav qhuav, tshawb nrhiav kev tsim cov ntawv tshiab xws li microsphere formulations thiab qhov ncauj formulations, kawm cov tshuaj pharmacokinetic tsis (xws li ib nrab- lub neej thiab bioavailability) nyob rau hauv ntau txoj kev tswj hwm, thiab muab cov lus qhia rau kev txhim kho kev ua raws li tus neeg mob.
Kev tshawb fawb txog kev siv tshuaj sib xyaw ua ke
Kawm txog kev sib koom ua ke ntawm Tirzepatide ua ke nrog metformin, SGLT -2 inhibitor, insulin thiab lwm yam tshuaj, txhim kho cov kev kho mob sib xyaw ua ke rau hom 2 mob ntshav qab zib thiab rog, thiab txo cov koob tshuaj thiab cov tshuaj tiv thaiv tsis zoo ntawm cov tshuaj ib leeg.
Preclinical kev tshawb fawb ntawm expanding indications
Kab mob plawv
Txhawm rau kawm txog kev txhim kho cov ntshav siab thiab atherosclerosis, saib xyuas cov txiaj ntsig ntawm Tirzepatide ntawm vascular endothelial kev ua haujlwm thiab cov qib inflammatory theem los ntawm cov qauv tsiaj, thiab ntsuas nws lub peev xwm hauv kev tiv thaiv kab mob plawv.
Cov kab mob neurodegenerative
Cov kev tshawb fawb ua ntej tau pom tias Tirzepatide tuaj yeem txhim kho cov ntshav qabzib ntau hauv neurodegeneration, kov yeej cov tshuaj insulin tsis kam, thiab xav tias yuav siv rau hauv kev tshawb fawb txog cov kab mob metabolic ntsig txog paj hlwb xws li Alzheimer's disease thiab Parkinson's disease.
Kab mob raum
Tshawb nrhiav nws txoj kev tiv thaiv ntawm ntshav qab zib nephropathy, kawm txog nws qhov cuam tshuam ntawm glomerular filtration rate thiab urinary protein theem, thiab muab kev tshawb fawb tshiab rau kev kho mob ntshav qab zib nephropathy.
Cim npe nrov: Tirzepatide lyophilized hmoov, Tuam Tshoj tirzepatide lyophilized hmoov manufacturers, lwm tus neeg
